GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions.

MLA

Brun, Sonia, et al. “GNS561, a Clinical-Stage PPT1 Inhibitor, Is Efficient against Hepatocellular Carcinoma via Modulation of Lysosomal Functions.” Autophagy, vol. 18, no. 3, Mar. 2022, pp. 678–94. EBSCOhost, https://doi.org/10.1080/15548627.2021.1988357.

APA

Brun, S., Bestion, E., Raymond, E., Bassissi, F., Jilkova, Z. M., Mezouar, S., Rachid, M., Novello, M., Tracz, J., Hamaï, A., Lalmanach, G., Vanderlynden, L., Legouffe, R., Stauber, J., Schubert, T., Plach, M. G., Courcambeck, J., Drouot, C., Jacquemot, G., … Halfon, P. (2022). GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions. Autophagy, 18(3), 678–694. https://doi.org/10.1080/15548627.2021.1988357

Chicago

Brun, Sonia, Eloïne Bestion, Eric Raymond, Firas Bassissi, Zuzana Macek Jilkova, Soraya Mezouar, Madani Rachid, et al. 2022. “GNS561, a Clinical-Stage PPT1 Inhibitor, Is Efficient against Hepatocellular Carcinoma via Modulation of Lysosomal Functions.” Autophagy 18 (3): 678–94. doi:10.1080/15548627.2021.1988357.